Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib
September 10, 2013 at 06:03 AM EDT
Exelixis, Inc. (NASDAQ: EXEL ) today announced that it has initiated CELESTIAL, a phase 3 pivotal trial comparing cabozantinib with placebo in patients with advanced hepatocellular carcinoma (HCC) who have
